

MOLECULAR DOCKING OF STIGMASTEROL AND CAMPESTEROL AS INHIBITORS OF ALZHEIMER'S DISEASE

Shanmugasundaram P¹, Ronald Darwin C^{2}, Parthiban S³, Theetchanya S⁴, Prakash R⁵, A R Vijayakumar⁶ &
Karthickeyan Krishnan⁷*

^{1,2,4,7}School of Pharmaceutical Sciences, Vels Institute of Science and Technology and Advanced Studies(VISTAS), Tamil Nadu.*

³Vels Medical College and Hospital, VISTAS Periyapalaya, Tiruvallur - 601102

⁵Department of Pharmacology, Crescent School of Pharmacy, B S Abdur Rahman Crescent Institute of Science and Technology, Chennai, Tamil Nadu, India.

⁶Department of Pharmacology, Faculty of Pharmacy, Sree Balaji Medical College and Hospital BIHER, Chromepet, Chennai, Tamilnadu 600044, India

ABSTRACT

Millions of people worldwide, mostly older individuals have been diagnosed with Alzheimer's disease (AD), a progressive and irreversible neurological disorder. A steady deterioration in cognitive function, including memory loss, language impairment, and challenges with abstract thought and problem solving, is an indication of AD. Acetylcholinesterase inhibitors, which raise acetylcholine levels in the brain, and memantine, which inhibits glutamate neurotransmitter action, are the most often prescribed medications for Alzheimer's disease because there is presently no known cure and the effectiveness of current treatments is limited. In this research, we explore the possibility of using the medicinal herb Cocciniaindica to treat Alzheimer's disease. In particular, we emphasized on the potential of stigmasterol and campesterol, two substances present in Cocciniaindica, to interact with target proteins linked to Alzheimer's disease.

KEYWORDS: *Alzheimer, Campesterol, Stigmasterol, Disorder, Targeted Proteins.*

Article History

Received: 16 Jun 2024 | Revised: 16 Jun 2024 | Accepted: 26 Jun 2024
